person · Reporting owner
Brainin Robert Lawrence
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC.CSBR · Entity 7013 | Director · CEO | July 16, 2025 | January 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHAMPIONS ONCOLOGY, INC.
Report date July 16, 2025 · Filed January 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2035-07-16 | Direct | 299,163 |
Reported balance
After 2025-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-16 · Grant · Acquired 225,000 · Balance 299,163 F1: The options vest and become exercisable as follows: 25% will vest on the one-year anniversary of the grant date on July 16, 2026; the balance will vest ratably at a rate of 1/36th each month thereafter. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2035-07-16 | Direct | 361,663 |
Reported balance
After 2025-07-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-16 · Grant · Acquired 62,500 · Balance 361,663 F2: The options will vest and be exercisable if the Company achieves EBITDA of $25 million over any consecutive four quarter period (based on the Company's fiscal year). |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2035-07-16 | Direct | 424,163 |
Reported balance
After 2025-07-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-16 · Grant · Acquired 62,500 · Balance 424,163 F3: The options will vest and be exercisable when $15 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year). |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2035-07-16 | Direct | 574,163 |
Reported balance
After 2025-07-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-16 · Grant · Acquired 150,000 · Balance 574,163 F4: The options will vest and be exercisable if (i) the Company achieves EBITDA of $35 million over any consecutive four quarter period (based on the Company's fiscal year) or (ii) when $30 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year). |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2035-07-16 | Direct | 674,163 |
Reported balance
After 2025-07-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-16 · Grant · Acquired 100,000 · Balance 674,163 F5: The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $16.00 Strike Price. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2035-07-16 | Direct | 774,163 |
Reported balance
After 2025-07-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-07-16 · Grant · Acquired 100,000 · Balance 774,163 F6: The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $24.00 Strike Price. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as follows: 25% will vest on the one-year anniversary of the grant date on July 16, 2026; the balance will vest ratably at a rate of 1/36th each month thereafter.
F2: The options will vest and be exercisable if the Company achieves EBITDA of $25 million over any consecutive four quarter period (based on the Company's fiscal year).
F3: The options will vest and be exercisable when $15 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year).
F4: The options will vest and be exercisable if (i) the Company achieves EBITDA of $35 million over any consecutive four quarter period (based on the Company's fiscal year) or (ii) when $30 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year).
F5: The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $16.00 Strike Price.
F6: The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $24.00 Strike Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2025 Filed Jan 30, 2026 20:55 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 100,000 | $7.80 Strike: $7.80 | $780,000.00 |
DisclosureSEC source: 0001628280-26-004381 · wk-form4_1769806532.xml · derivative · entry 6 Brainin Robert Lawrence · CIK 0002088015 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 774,163 Underlying: Common Stock · 100,000 shares Expires 2035-07-16 F6 · derivative.exercise_date: The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $24.00 Strike Price. Read SEC document |
| July 16, 2025 Filed Jan 30, 2026 20:55 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 100,000 | $7.80 Strike: $7.80 | $780,000.00 |
DisclosureSEC source: 0001628280-26-004381 · wk-form4_1769806532.xml · derivative · entry 5 Brainin Robert Lawrence · CIK 0002088015 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 674,163 Underlying: Common Stock · 100,000 shares Expires 2035-07-16 F5 · derivative.exercise_date: The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $16.00 Strike Price. Read SEC document |
| July 16, 2025 Filed Jan 30, 2026 20:55 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 150,000 | $7.80 Strike: $7.80 | $1,170,000.00 |
DisclosureSEC source: 0001628280-26-004381 · wk-form4_1769806532.xml · derivative · entry 4 Brainin Robert Lawrence · CIK 0002088015 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 574,163 Underlying: Common Stock · 150,000 shares Expires 2035-07-16 F4 · derivative.exercise_date: The options will vest and be exercisable if (i) the Company achieves EBITDA of $35 million over any consecutive four quarter period (based on the Company's fiscal year) or (ii) when $30 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year). Read SEC document |
| July 16, 2025 Filed Jan 30, 2026 20:55 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 62,500 | $7.80 Strike: $7.80 | $487,500.00 |
DisclosureSEC source: 0001628280-26-004381 · wk-form4_1769806532.xml · derivative · entry 3 Brainin Robert Lawrence · CIK 0002088015 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,163 Underlying: Common Stock · 62,500 shares Expires 2035-07-16 F3 · derivative.exercise_date: The options will vest and be exercisable when $15 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year). Read SEC document |
| July 16, 2025 Filed Jan 30, 2026 20:55 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 62,500 | $7.80 Strike: $7.80 | $487,500.00 |
DisclosureSEC source: 0001628280-26-004381 · wk-form4_1769806532.xml · derivative · entry 2 Brainin Robert Lawrence · CIK 0002088015 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,663 Underlying: Common Stock · 62,500 shares Expires 2035-07-16 F2 · derivative.exercise_date: The options will vest and be exercisable if the Company achieves EBITDA of $25 million over any consecutive four quarter period (based on the Company's fiscal year). Read SEC document |
| July 16, 2025 Filed Jan 30, 2026 20:55 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 225,000 | $7.80 Strike: $7.80 | $1,755,000.00 |
DisclosureSEC source: 0001628280-26-004381 · wk-form4_1769806532.xml · derivative · entry 1 Brainin Robert Lawrence · CIK 0002088015 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,163 Underlying: Common Stock · 225,000 shares Expires 2035-07-16 F1 · derivative.exercise_date: The options vest and become exercisable as follows: 25% will vest on the one-year anniversary of the grant date on July 16, 2026; the balance will vest ratably at a rate of 1/36th each month thereafter. Read SEC document |
| November 12, 2024 Filed Jan 30, 2026 17:15 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 23,030 | $4.64 Strike: $4.64 | $106,859.20 |
DisclosureSEC source: 0001628280-26-004342 · wk-form4_1769793351.xml · derivative · entry 4 Brainin Robert Lawrence · CIK 0002088015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,163 Underlying: Common Stock · 23,030 shares Expires 2034-11-12 F4 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 12, 2024, February 12, 2025, May 12, 2025 and August 12, 2025, respectively. Read SEC document |
| November 03, 2023 Filed Jan 30, 2026 17:15 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 19,070 | $5.51 Strike: $5.51 | $105,075.70 |
DisclosureSEC source: 0001628280-26-004342 · wk-form4_1769793351.xml · derivative · entry 3 Brainin Robert Lawrence · CIK 0002088015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,133 Underlying: Common Stock · 19,070 shares Expires 2033-11-03 F3 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 3, 2023, February 3, 2024, May 3, 2024 and August 3, 2024, respectively. Read SEC document |
| November 01, 2022 Filed Jan 30, 2026 17:15 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 14,130 | $7.00 Strike: $7.00 | $98,910.00 |
DisclosureSEC source: 0001628280-26-004342 · wk-form4_1769793351.xml · derivative · entry 2 Brainin Robert Lawrence · CIK 0002088015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,063 Underlying: Common Stock · 14,130 shares Expires 2032-11-01 F2 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2022, February 1, 2023, May 1, 2023 and August 1, 2023, respectively. Read SEC document |
| November 05, 2021 Filed Jan 30, 2026 17:15 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 9,901 | $10.10 Strike: $10.10 | $100,000.10 |
DisclosureSEC source: 0001628280-26-004342 · wk-form4_1769793351.xml · derivative · entry 1 Brainin Robert Lawrence · CIK 0002088015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,933 Underlying: Common Stock · 9,901 shares Expires 2031-11-05 F1 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2021, February 5, 2022, May 5, 2022 and August 5, 2022, respectively. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.